DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the stock.

Separately, JMP Securities restated a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Trading Up 2.8 %

DBVT opened at $4.23 on Wednesday. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $9.09. The company has a market cap of $86.90 million, a price-to-earnings ratio of -0.94 and a beta of 0.67. The company’s fifty day moving average price is $4.04 and its two-hundred day moving average price is $3.83.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent reporting period. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.